

# Elena Rodriguez-Vieitez

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5573279/elena-rodriguez-vieitez-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36  
papers

1,130  
citations

14  
h-index

33  
g-index

42  
ext. papers

1,526  
ext. citations

8.8  
avg. IF

4.76  
L-index

#	Paper	IF	Citations
36	Tau PET imaging in neurodegenerative tauopathies-still a challenge. <i>Molecular Psychiatry</i> , <b>2019</b> , 24, 1112-1134	11.2	251
35	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. <i>Brain</i> , <b>2016</b> , 139, 922-36	11.2	177
34	Tau PET imaging: present and future directions. <i>Molecular Neurodegeneration</i> , <b>2017</b> , 12, 19	19	172
33	Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 1119-32	8.8	81
32	Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. <i>Scientific Reports</i> , <b>2015</b> , 5, 16404	4.9	79
31	Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 232-236	5.2	60
30	Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1071-7	8.9	47
29	Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1369-1382	8.8	45
28	Comparability of [F]THK5317 and [C]PIB blood flow proxy images with [F]FDG positron emission tomography in Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2017</b> , 37, 740-749	7.3	35
27	Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 2831-2847	8.8	25
26	Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis. <i>Neurology</i> , <b>2021</b> ,	6.5	23
25	Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 348-356	8.8	23
24	Altered perivascular fibroblast activity precedes ALS disease onset. <i>Nature Medicine</i> , <b>2021</b> , 27, 640-646	50.5	19
23	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. <i>Neurology</i> , <b>2020</b> , 94, e2026-e2036	6.5	17
22	Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach. <i>Methods in Molecular Biology</i> , <b>2018</b> , 1750, 231-251	1.4	14
21	Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 652-663	1.2	11
20	Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , <b>2017</b> , 23, 195-203	3.1	10

19	Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 47, 661-7	4.3	10
18	Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid- $\beta$ positivity. <i>Molecular Psychiatry</i> , <b>2020</b> ,	15.1	7
17	Comparison of subtyping methods for neuroimaging studies in Alzheimer's disease: a call for harmonization. <i>Brain Communications</i> , <b>2020</b> , 2, fcaa192	4.5	5
16	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 45	9	5
15	Clinical impact of F-FDG-PET among memory clinic patients with uncertain diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 612-622	8.8	5
14	PET Imaging of Monoamine Oxidase B <b>2021</b> , 521-545		2
13	Towards harmonizing subtyping methods for PET and MRI studies of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e042807	1.2	1
12	Longitudinal cognitive decline in autosomal-dominant Alzheimer's disease varies with mutations in APP and PSEN1 genes. <i>Neurobiology of Aging</i> , <b>2019</b> , 82, 40-47	5.6	1
11	IC-03-03: COMPARISON OF MEASUREMENTS OF CEREBRAL BLOOD FLOW BY EARLY FRAMES OF 11C-DEUTERIUM-L-DEPRENYL (11C-DED) AND 11C-PIB PET TRACERS AT DIFFERENT STAGES OF ALZHEIMER'S DISEASE <b>2014</b> , 10, P7-P7		1
10	Plasma sTREM2: a potential marker of cerebrovascular injury in neurodegenerative disorders. <i>Brain</i> , <b>2021</b> ,	11.2	1
9	Association of cortical microstructure with amyloid- $\beta$ and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	1
8	Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 84, 103-117	4.3	0
7	The relationship between cortical microstructural changes and in vivo amyloid- $\beta$ and tau in aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e041626	1.2	
6	P3-214: COMPARISON OF MEASUREMENTS OF CEREBRAL BLOOD FLOW BY EARLY FRAMES OF 11C-DEUTERIUM-L-DEPRENYL (11C-DED) AND 11C-PIB PET TRACERS AT DIFFERENT STAGES OF ALZHEIMER'S DISEASE <b>2014</b> , 10, P709-P709		
5	IC-P-126: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease <b>2015</b> , 11, P86-P86		
4	O1-02-03: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease <b>2015</b> , 11, P127-P127		
3	[P4533]: GENOTYPE-DEPENDENT LONGITUDINAL TRAJECTORIES OF COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE <b>2017</b> , 13, P1554		
2	P4-349: EARLY-PHASE [11C]PIB PET is Comparable to [18F]FDG PET as a Marker of Disease Progression in Alzheimer's Disease <b>2016</b> , 12, P1171-P1171		

1 S2-01-02: PET MARKERS OF ASTROCYTES **2019**, 15, P514-P514